title: Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
abstract: We report two cases of multiple myeloma relapse and progression following a combination of autologous stem cell transplantation and non-myeloablative allogeneic stem cell transplantation. After failure of donor lymphocyte infusions and thalidomide salvage therapy, the patients were treated successfully with bortezomib and eventually underwent a second non-myeloablative allogeneic stem cell transplantation.
authors.forename: Daniele
authors.initials: D
authors.lastname: Mattei
authors.forename: Nicola
authors.initials: N
authors.lastname: Mordini
authors.forename: Riccardo
authors.initials: R
authors.lastname: Vigna Taglianti
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Davide
authors.initials: D
authors.lastname: Rapezzi
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D016879:Salvage Therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D013792:Thalidomide / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib